COMPARATIVE EFFECTIVENESS OF PERINDOPRIL AND LOSARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY

Aim. To assess the antihypertensive effectiveness of perindopril А and losartan and their influence on the main cardiovascular risk factors among patients with arterial hypertension and obesity. Material and methods. This single-blind, randomised, comparative parallel study included patients either untreated with antihypertensive medications or in the end of the two-week wash-out period. All patients were randomised (random envelope method) into 2 groups: Group I (n=30) received perindopril А (Prestarium A, Servier; 10 mg/d), while Group II (n=30) was administered losartan (Cozaar, Merck Sharp & Dohme; 100 mg/d) for 24 weeks. The examination included 24-hour blood pressure monitoring (SpaceLabs 90207, USA), the measurement of pulse wave velocity (PWV), augmentation index, and central aortal pressure (Sphygmocor), and standard echocardiography (EchoCG) (ALOKA prosound L7 premier). Results. In the perindopril А group, 24-hour levels of systolic and diastolic blood pressure (SBP, DBP) decreased by 15,2% and 18,1%, respectively; in the losartan group, this reduction was 7,8% (p<0,05) and 14,9%, respectively. Perindopril А more effectively, compared to losartan, reduced left ventricular myocardial thickness and myocardial mass index – by 5,3% and 14,3%, respectively, vs. 1,2% and 5,5% (p<0,05). Perindopril А also reduced the carotid-femoral PVW (CF PWV) by 28,9% and the carotid-radial PVW (CR PWV) by 25,8%, compared to 4,1% and 15,7% (p<0,05) in the losartan group. Augmentation index and central aortal pres in the losartan group. Augmentation index and central aortal pressure decreased by 17,4% and 7,5%, respectively, in the perindopril А group. In the losartan group, the respective figures were 3,5% and 1,3% (p<0,05). An important finding for the patients with arterial hypertension and obesity was a reduction in blood leptin levels – by 29,7% vs. 6,9% in participants treated with perindopril А vs. losartan (p<0,05). Conclusion. Perindopril А is more suitable for the arterial hypertension treatment in obese patients, since it not only more effectively, compared to losartan, reduced BP, but also demonstrated more beneficial effects on the cardiovascular risk factors in this clinical group (including normalisation of lipid and carbohydrate metabolism or improvement of anthropometric parameters).

Hyperuricemia, gout, arterial hypertension, pulse wave velocity, losartan

1. PoggiL, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol (1994) 10 (Suppl. D):21D–24D.

2. van Zwieten P.A. Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences. Neth Heart J. 2006; 14 (11):381–387.

3. Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther. 2004;11:199–205.

4. Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19:667–674.

5. Ying Li., Song Yaoming et al. Effects of perindopril and candesartan on left ventricular remodeling and serum ET-1, IL-6 and MMP-9 levels in patients with chronic heart failure. Acta Academiae Medicinae Militaris Tertiae 2011; 06:127–131.

6. B hlen L, Bienz R, Doser M, et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996; 27 (6):770–6.

7. Fogari R et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:316–320.

8. Mathai M, Find all citations by this author (default).

9. Naik S. et al Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats International Journal of Obesity 2008; 32:1576–1584.

10. Brasier A., Recinos A., Eledrisi M. Vascular Inflammation as a Cardiovascular Risk Factor Principles of Molecular Cardiology. Contemporary Cardiology 2005; VI:577–604.

11. Gabbani S. et al. Effects of perindopril on carbohydrate and lipoprotein metabolism in essential hypertension. The American Journal of Medicine 1992; 4 (2):95–97.

12. LI Yuan, WANG Xiao-ming et al. Effects of perindopril on sICAM-1 and Fas/Apo-1 in peripheral blood of elderly patients with congestive heart failure. Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Disease 2004; 02:112–116.

13. Madej A, Buldak L, et al. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther 2009; 47 (11):686–94.

14. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptorinteraction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34:745–750.

15. Mychka V.B., Chazova I.E. The use of perindopril in patients with mild moderate arterial hypertension and metabolic syndrome. Arterial Hypertension 2002; 8:36–41. Russian (Мычка В.Б., Чазова И.Е. Применение периндоприла у больных мягкой умеренной артериальной гипертензией и метаболическим синдромом. Артериальная гипертензия 2002; 8:36–41).

16. Yoshiji, H., Kuriyama, S., Kawata, M. et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001; 7:1073–1078.

17. Lubel J. Liver Disease and the Renin-angiotensin System: Recent Discoveries and Clinical Implications. Gastroenterol Hepatol. 2008; 23 (9):1327–1338.